European Commission expands Stelara for paediatric moderate to severe plaque psoriasis
January 24, 2020Research and Development Europe, Janssen, Stelara, pharma
Janssen’s Stelara (ustekinumab) has seen its label expanded in Europe to include the treatment of moderate to severe plaque psoriasis …
FDA puts MDMA therapy for PTSD on its Expanded Access program
January 24, 2020Medical Communications Expanded Access, MAPS, MDMA, PTSD, pharmaceuticals, psychedelics, war
The FDA has made MDMA treatment for PTSD more accessible by putting it on the Expanded Access program. 10 sites …
Roche’s Tecentriq falls short as an adjuvant monotherapy in muscle-invasive urothelial cancer
January 24, 2020Medical Communications, Sales and Marketing Cancer, Roche, pharma, tecentriq, trial failure
Roche has released an update on the development of its immunology Tecentriq (atezolizumab), making it known that the drug failed …
UK tests 14 people for Chinese coronavirus
January 24, 2020Medical Communications Chinese Coronavirus, NHS, Public Health England, Viral outbreaks, Viral pnemonia, coronavirus, epidemic
14 people in the UK have been tested for the Chinese coronavirus, according to Public Health England (PHE). In Scotland, …
Former Insys sales exec sentenced to a year in prison for offering lap dances to encourage fentanyl spray prescriptions
January 23, 2020Medical Communications, Sales and Marketing insys, pharma
A sales executive at the disgraced and bankrupted firm Insys who was accused of offering lap dances in order to …
Oxford Immunotec to supply TB diagnostic tests to china to aid in coronavirus crisis
January 23, 2020Medical Communications, Sales and Marketing China, Oxford Immunotec Global, Wuhan, coronavirus, pharma
As fears rise over the impact and spread of Chinese coronavirus following news of a rising death toll and the …
NICE declines to recommend Astellas’ Xospata in rlapsed/refractory FLT3+ acute myeloid leukaemia
January 23, 2020Sales and Marketing Astellas, NHS, NICE, UK, Xospata, acute myeloid leukaemia
The latest in a series of rejections over the past week, NICE has revealed that it has knocked back the …
Roche’s risdiplam hits main goal in infants with spinal muscular atrophy
January 23, 2020Research and Development Roche, pharma, risdiplam, spinal muscular atrophy
Roche has announced the success of its survival motor neuron-2 (SMN2) splicing modifier risdiplam in a new trial investigating its …
China approves Roche cancer drug Kadcyla
January 22, 2020Business Services China, Roche, breast cancer, cancer treatment, oncology
China has approved the import of Roche’s drug for breast cancer, just after it recently won expanded approval in the …
FDA fast-tracks GSK’s multiple myeloma drug after priority review
January 22, 2020Research and Development BCMA, FDA, GSK, Phase 2 Trials, Phase Trials, multiple myeloma, myeloma
The FDA has fast tracked GlaxoSmithKline (GSK) antibody drug conjugate (ADC) belantamab mafodotin, for the treatment of patients with refractory …
Horizon’s Tepezza becomes first and only FDA-approved drug for thyroid eye disorder
January 22, 2020Research and Development FDA, Horizon Therapeutics, Tepezza, pharma
Horizon Therapeutics has announced that its IGF-1R inhibitor Tepezza (teprotumumab-trbw) has become the first and only therapy approved by the …
Chinese coronavirus set to be put on international health emergency list
January 22, 2020Research and Development Ebola, Public Health Emergency, WHO, World Health Organisation, Wuhan, polio, swine flu
The World Health Organisation (WHO) is expected to trigger a Public Health Emergency over the Wuhan coronavirus outbreak, meaning it …
No NICE recommendation for AstraZeneca’s Tagrisso in EGFR+ lung cancer
January 22, 2020Research and Development, Sales and Marketing AstraZeneca, NICE, Tagrisso, pharma
AstraZeneca’s Tagrisso (osimertinib) has been knocked back for routine use on the NHS in England and Wales by the drug …
Novartis establishes its new legal entity in Vietnam
January 22, 2020Research and Development Novartis, Novartis Vietnam, oncology, pharma
Novartis has inaugurated its new legal entity in Vietnam, Novartis Vietnam Co Ltd, and has become one of the first …
EU approval for Roche’s Polivy combo in relapsed/refractory B-cell lymphoma
January 21, 2020Manufacturing and Production, Sales and Marketing Cancer, Polivy, Roche, lymphoma, pharma
The European Commission has awarded conditional marketing approval to Roche’s Polivy (polatuzumab vedotin), it has been revealed.
Janssen’s ulcerative colitis medicine not recommended by NICE for use in adults
January 21, 2020Manufacturing and Production IBS, Irrated Bowels, NHS, NICE, bowel, ulcerative colitis
NICE has published draft guidance which does not recommend Stelara (ustekinumab) for treating moderately to severely active ulcerative colitis in …
Jazz Pharma’s Sunosi becomes first EU-approved drug of its kind in narcolepsy and sleep apnoea
January 21, 2020Manufacturing and Production, Sales and Marketing jazz pharmaceuticals, narcolepsy, pharma
Jazz Pharmaceuticals has secured approval from the European Commission for Sunosi (solriamfetol), it has emerged, as a therapy to improve …
Cardiff University team discovers new method of killing cancers
January 21, 2020Manufacturing and Production Cancer, Cancer cures, Cancerous, Cardiff University, T cell, cells, immune system, immunity, t-cell
A team at Cardiff University have discovered a new part of the human immune system that could be harnessed to …
Novartis’ Mayzent granted license by the European Medicines Agency
January 21, 2020Manufacturing and Production CNS, European Medicines Agency, NHS, NICE, Novartis
The European Medicines Agency (EMA) has granted a licence for the use of Mayzent (siponimod) in the treatment of certain …
FDA warning letters to Indian pharmaceutical companies double in 2019
January 20, 2020Sales and Marketing Indian Pharma, Indian Pharmaceuticals
Indian pharmaceutical firms received more than double the amount of warning letters in the first ten months of 2019 compared …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
